In the last trading session, 3.12 million shares of the Spyre Therapeutics Inc (NASDAQ:SYRE) were traded, and its beta was 2.88. Most recently the company’s share price was $26.90, and it changed around -$1.77 or -6.17% from the last close, which brings the market valuation of the company to $1.38B. SYRE currently trades at a discount to its 52-week high of $47.97, offering almost -78.33% off that amount. The share price’s 52-week low was $8.75, which indicates that the current value has risen by an impressive 67.47% since then. We note from Spyre Therapeutics Inc’s average daily trading volume that its 10-day average is 0.56 million shares, with the 3-month average coming to 498.40K.
Spyre Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.10. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 0 recommended SYRE as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Spyre Therapeutics Inc is expected to report earnings per share of -0.98 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Instantly SYRE has showed a red trend with a performance of -6.17% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 36.98 on recent trading dayincreased the stock’s daily price by 27.26%. The company’s shares are currently up 25.00% year-to-date, but still down -24.90% over the last five days. On the other hand, Spyre Therapeutics Inc (NASDAQ:SYRE) is -17.05% down in the 30-day period. We can see from the shorts that 8.25 million shares have been sold at a short interest cover period of 21.97 day(s).
The consensus price target as assigned by Wall Street analysts is $45, which translates to bulls needing to increase their stock price by 40.22% from its current value. Analyst projections state that SYRE is forecast to be at a low of $40 and a high of $71.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
Spyre Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -25.46 percent over the past six months and at a 85.06% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 75.72% in revenue this quarter, and will report an increase of 31.25% in the next quarter. The year-over-year growth rate is expected to be 194.86%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 2.62M in revenue for the current quarter. 5 analysts expect Spyre Therapeutics Inc to make 4M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at ∞%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 23.71%.
SYRE Dividends
Spyre Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
FAIRMOUNT FUNDS MANAGEMENT LLC, with 8.8668% or 4.02 million shares worth $94.47 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
